Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
Zacks News
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $87.42 in the latest trading session, marking a +0.63% move from the prior day.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Emergent (EBS) Initiates Study on Lassa Virus Vaccine Candidate
by Zacks Equity Research
Emergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Merck (MRK) Stock Moves -1.06%: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $86.23, marking a -1.06% move from the previous day.
3 Stocks to Buy in September as the Market Falls and Rates Rise
by Benjamin Rains
Diving into three dividend-paying stocks that could be poised to help investors profit in September and beyond.
Company News for Aug 29, 2022
by Zacks Equity Research
Companies in The News Are: AFRM,FTCH,SGEN,MRK,DELL
The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer
by Zacks Equity Research
Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.
Iovance (IOVA) Starts Rolling BLA With FDA for Melanoma Therapy
by Zacks Equity Research
Iovance (IOVA) starts a rolling BLA submission with the FDA seeking approval for its lead pipeline candidate in advanced melanoma patients. The filing is expected to be completed by fourth-quarter 2022.
Pharma Stock Roundup: NVS to Spin Off Sandoz; JNJ, MRK, ABBV's FDA Updates
by Kinjel Shah
Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Bristol Myers (BMY) Up 14.6% YTD: Will the Performance Continue?
by Zacks Equity Research
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue on label expansion of existing drugs.
Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead?
by Zacks Equity Research
Lilly (LLY) expects to launch five new medicines by 2023-end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.
J&J (JNJ) Gets EU Nod for Multiple Myeloma Drug Tecvayli
by Zacks Equity Research
J&J (JNJ) gets approval for Tecvayli (teclistamab) for the treatment of relapsed and refractory multiple myeloma. This marks the first approval for Tecvayli in any country.
AstraZeneca (AZN) Gets Japan Nod for Expanded Use of 3 Drugs
by Zacks Equity Research
The Japanese Ministry of Health, Labour, and Welfare approved AstraZeneca's (AZN) three marketed drugs, Lynparza, Tagrisso and Ultomiris, for three different indications in Japan.
Phibro (PAHC) Q4 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Phibro (PAHC) posts better-than-expected revenues for the fiscal fourth quarter, with robust growth across all segments.
Merck (MRK) Gets FDA Fast Track Tag for Anticoagulant Therapy
by Zacks Equity Research
A phase II study is ongoing on Merck's (MRK) MK-2060 in people with end-stage renal disease receiving hemodialysis.
Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Medtronic (MDT) posts better-than-expected results for the fiscal first quarter and maintains earnings and sales outlook for the full year.
Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTCS
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
by Kinjel Shah
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
What's in the Cards for Medtronic (MDT) in Q1 Earnings?
by Zacks Equity Research
Going by the industry-wide macro trend, we expect Medtronic (MDT) to once again report an adverse effect related to the global supply chain issues in fiscal Q1.
Zacks Market Edge Highlights: Merck, PepsiCo, Honeywell, Microsoft and PNC Financial
by Zacks Equity Research
Merck, PepsiCo, Honeywell, Microsoft and PNC Financial have been highlighted in this Market Edge article.